Strs Ohio Increases Position in GreenLight Biosciences Holdings (NASDAQ:GRNA)

Strs Ohio increased its stake in shares of GreenLight Biosciences Holdings (NASDAQ:GRNAGet Rating) by 403.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,600 shares of the company’s stock after buying an additional 13,300 shares during the quarter. Strs Ohio’s holdings in GreenLight Biosciences were worth $38,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Penserra Capital Management LLC purchased a new stake in shares of GreenLight Biosciences during the first quarter valued at $25,000. Arizona State Retirement System purchased a new stake in shares of GreenLight Biosciences during the second quarter valued at $29,000. Rhumbline Advisers purchased a new stake in shares of GreenLight Biosciences during the second quarter valued at $29,000. Legal & General Group Plc purchased a new stake in shares of GreenLight Biosciences during the second quarter valued at $33,000. Finally, Congress Wealth Management LLC DE purchased a new stake in shares of GreenLight Biosciences during the second quarter valued at $44,000. 24.41% of the stock is owned by hedge funds and other institutional investors.

GreenLight Biosciences Stock Up 4.8 %

GRNA stock opened at $1.10 on Monday. The company’s 50-day simple moving average is $1.23 and its 200-day simple moving average is $2.01. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.37 and a quick ratio of 3.37. GreenLight Biosciences Holdings has a 52-week low of $1.00 and a 52-week high of $15.80.

GreenLight Biosciences (NASDAQ:GRNAGet Rating) last posted its earnings results on Wednesday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter. The firm had revenue of $1.73 million for the quarter.

Analyst Ratings Changes

GRNA has been the topic of several recent research reports. Credit Suisse Group initiated coverage on shares of GreenLight Biosciences in a report on Friday, October 14th. They issued an “outperform” rating and a $5.50 price target on the stock. Canaccord Genuity Group initiated coverage on shares of GreenLight Biosciences in a report on Thursday, December 8th. They issued a “buy” rating and a $4.00 price target on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of GreenLight Biosciences in a report on Thursday, December 8th. They issued a “buy” rating and a $4.00 price target on the stock.

GreenLight Biosciences Profile

(Get Rating)

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

Read More

Want to see what other hedge funds are holding GRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GreenLight Biosciences Holdings (NASDAQ:GRNAGet Rating).

Institutional Ownership by Quarter for GreenLight Biosciences (NASDAQ:GRNA)

Receive News & Ratings for GreenLight Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GreenLight Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.